XenoPort Shares Plunge On Negative Phase IIb Study

Shares of XenoPort

have plunged on negative Phase IIb study. The Santa Clara, California-based developer, along with GlaxoSmithKline

, said that a Phase IIb study for gabapentin enacarbil failed to “demonstrate a statistically significant improvement compared to placebo as a prophylactic treatment for migraine headaches." XNPT’s shares plunged 27.28% to $6.45 at 9:45 am EDT. Read more

Learn how to find the best

for free.